

## Notice of End of Replacement of Medications

An Act respecting prescription drug insurance  
(chapter A-29.01, s. 60.1)

The Régie de l'assurance maladie du Québec hereby gives notice that it is cancelling the notice of replacement published on its website on [28 October 2014](#) and in force as of 30 September 2014, which authorized temporary use of the following alternative (hereinafter referred to as the "alternative"):

| <b>Code</b> | <b>Manufacturer</b> | <b>Generic name, form, strength</b> |
|-------------|---------------------|-------------------------------------|
| 99101154    |                     | Cefixime, Oral Susp., 100 mg/5 mL   |

That alternative was a replacement for the following medication appearing on the List of Medications attached to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan:

| <b>Code</b> | <b>Manufacturer</b> | <b>Brand name, form, strength</b> |
|-------------|---------------------|-----------------------------------|
| 00868965    | SanofiAven          | Suprax, Oral Susp., 100 mg/5 mL   |

Consequently, use of the alternative is no longer authorized.

This notice has effect from 20 June 2016. Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it, in accordance with section 60.1 of the Act respecting prescription drug insurance.

Québec, 14 June 2016

Original signed by

Chantal Garcia  
Secretary General of the  
Régie de l'assurance maladie du Québec